Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

Natrol new at Expo West: Natrol announces March 5 it would launch new products at Expo West in Anaheim, Calif., including BioSil, a "bio-available, collagen generating supplement" shown to reduce fine lines and wrinkles in skin, thicken and strengthen hair and strengthen nails, as well as promote bone mineral density and healthy joints. A 30-count 5 mg bottle carries an SRP of $18.95. Another product Natrol planned to unveil at the March 13-15 event is Natrol 5-HTP Time-Release 200 mg, a "drug-free, plant-derived source of an amino acid that naturally increases the body's level of serotonin to help promote relaxation, calm and greater appetite control, as well as helping to support a more positive mood." A 30-count bottle carries an SRP of $24.99...

You may also be interested in...



Cholesstrinol lawsuit

SourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)

Cholesstrinol lawsuit

SourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)

Cholesstrinol lawsuit

SourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel